Brief: Tiziana Announces Initiation Of Phase 1B Clinical Trial In Crohn's Disease Patients To Evaluate Oral Capsules Of Foralumab, A Fully Human Anti-CD3 Monoclonal Antibody
25/03/2022 11:06
March 25 (Reuters) - Tiziana Life Sciences Ltd TLSA.O :
* TIZIANA ANNOUNCES INITIATION OF PHASE 1B CLINICAL TRIAL IN
CROHN'S DISEASE PATIENTS TO EVALUATE ORAL CAPSULES OF FORALUMAB,
A FULLY HUMAN ANTI-CD3 MONOCLONAL ANTIBODY
* TIZIANA LIFE SCIENCES LTD - PHASE 1B CLINICAL TRIAL IN
CROHN'S
DISEASE PATIENTS IS ANTICIPATED TO BE COMPLETED BY Q4, 2022
Source text for Eikon: ID:nGNX4CmfBX
Further company coverage: TLSA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tiziana Life Sciences
See all newsBrief: Tiziana Announces New Positive Clinical Data For Intranasal Foralumab In Non-Active Secondary Progressive Multiple Sclerosis
U.S. STOCKS ON THE MOVE -Viatris, Clear Secure, Bicara
U.S. STOCKS ON THE MOVE-Sharps Technology, Whirlpool, Applovin
U.S. STOCKS ON THE MOVE-Oracle, Vanda, Keysight
Tiziana Life Sciences rises as nasal MS drug shows promise in early study